Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

With renewed financial strength, WeightWatchers accelerates its transformation with the appointment of key executives including Dr. Kim Boyd as Chief Medical Officer The Company is advancing its first ...

DelveInsight's Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Wave Life Sciences Ltd. shows promise with AATD, DMD, and Huntington's programs. Click for my updated look at WVE stock and ...

DELAWARE, DE, UNITED STATES, July 4, 2025 /EINPresswire.com/ -- The global Attention Deficit Hyperactivity Disorder (ADHD) market is anticipated to reach USD 18.3 billion by 2025, as a result of ...